CS Paper Radar

Automated PD-L1 Tumor Proportion Scoring with Uncertainty-Guided Triage in Non-Small Cell Lung Cancer

Kesi Xu, Ayesha Azam, Tanvier Kaur, Monika Kondratowicz, Kinza Asim, Brinder Chohan, Paapa Appiah-Odame, Zhao Chen, David Snead, Nasir Rajpoot

cs.CV eess.IV ·submitted 2026-11-12 15:01 UTC · v1
hot direction

Abstract

Programmed death-ligand 1 (PD-L1) tumor proportion score (TPS) informs immunotherapy selection in non-small cell lung cancer. Near the 1% and 50% cutoffs, the score should also indicate when closer review is warranted. We designed a three-stage framework to follow the sequence of TPS assessment. Stage 1 identifies tumor regions and excludes macrophage-rich patches. Stage 2, a dual-branch cell counting network (D2Count-Net), counts PD-L1-positive and PD-L1-negative tumor cells in these regions to calculate TPS. Stage 3, TPS-Guard, an uncertainty-guided triage mechanism, reports model uncertainty as the disagreement among independently trained models, refers the most uncertain slides, and flags scores near the 1% or 50% cutoff when model estimates disagree across that cutoff. Flags state the reason for referral or alert the pathologist to possible scoring errors on auto-reported slides. In a retrospective, single-center study, 154 whole-slide images were scored by three pathologists, and the model and each pathologist were compared in turn with the mean of the other two. On the 114 slides unseen in training, model mean absolute error (MAE) was 6.96 percentage points, within the range of the three pathologists (4.24 to 8.29), and model uncertainty correlated with absolute TPS error (Spearman rho = 0.77) and inter-pathologist disagreement (rho = 0.71). After referral of the 15% most uncertain slides, model and pathologist MAE both decreased. Applied without retraining to an external, publicly available dataset, TPS-Guard still directed review to higher-error cases, and referring more uncertain cases raised sensitivity at the 50% cutoff. TPS-Guard provides reasons for reviewing individual automated scores and identifies slides that also produce greater disagreement among pathologists. Prospective reader studies should assess TPS-Guard's effect on TPS reporting.

Comment
55 pages (29-page main text with 5 figures and 3 tables, followed by 26 pages of supplementary material)

Closest papers

Nearest neighbours by meaning across the whole index.

AI-assisted mitotic counting improves reproducibility and efficiency across multiple tumour types

cs.AI ·2026-10-01 ·Simon Graham, Mostafa Jahanifar, Quoc Dang Vu, Vygante Maskoliunaite, Donatas Petroska +13 more
similarity 0.66
Abstract

Mitotic counting is an important component of tumour grading, diagnosis and prognostic assessment across several tumour types, but manual assessment is time-consuming and subject to inter-pathologist variability. To help address these challenges, we developed MitPro, an AI tool designed to improve consistency and efficiency by directing pathologists towards regions with the highest predicted mitotic activity and highlighting mitotic figures for review, while retaining pathologist control over region selection and the final count. We evaluated its effect on the reproducibility and efficiency of mitotic counting in a retrospective, non-interventional, paired reader study comprising 385 whole-slide images from 3 centres in 3 countries and 7 tumour types using 3 different scanners. 13 pathologists participated, with each slide assessed independently by 3 pathologists without AI assistance and again with AI assistance after a minimum 2 week washout period. Across all slides, AI-assisted counting increased the intraclass correlation coefficient from 0.589 to 0.949. Mean pathologist-level median assessment time decreased from 286.4 to 127.8 seconds, corresponding to an average saving of 151.8 seconds per assessment. Improvements in agreement and efficiency were also observed in supporting analyses using HALO AP and Sectra image management systems and in 2 additional tumour types outside the main study population. AI-assisted assessment was associated with a subtle shift towards higher mitotic counts and scores, consistent with identification of more active mitotic hotspots and fewer missed mitotic figures. The frequency of score change between unassisted and AI-assisted assessment was comparable with inter-pathologist variation during routine counting. These findings support the use of MitPro as an assistive tool for more consistent and efficient mitotic assessment in routine practice.

0.22

SCOUT: Risk-Guided Foundation-Model Escalation for Robust Tissue Detection in Whole-Slide Images

cs.CV ·2026-11-18 ·Cristian Tommasino, Antonio M. Rinaldi
benchmarkcode/data similarity 0.64
Abstract

Reliable tissue detection is essential for whole-slide image analysis, yet high average segmentation accuracy can conceal failures involving pale tissue, small fragments, and heterogeneous staining. Pathology foundation models offer transferable representations, but exhaustive inference is computationally demanding and may introduce false-positive tissue predictions. We propose SCOUT (Selective Correction of Uncertain Tissue), a risk-guided cascade that selectively refines an initial thumbnail-based tissue mask. A lightweight audit network estimates the spatial distribution of segmentation errors and prioritizes candidate regions for processing by a frozen pathology foundation model. An asymmetric consensus rule integrates the resulting predictions with the initial mask to recover missed tissue while limiting false positives. A calibrated slide-level review score additionally controls the marginal rate of unflagged case-group failures under the calibration assumptions. Evaluation on a public multi-source, multi-stain benchmark shows that SCOUT reduces the proportion of case groups requiring mask correction from 38.1% for the best released detector to 18.6%, with particularly pronounced improvements in immunohistochemistry. Source-held-out experiments demonstrate better generalization than a segmentation network trained on the same annotations, while selective inference achieves an observed failure rate no higher than processing all candidate regions. Downstream, lymph-node classification with SCOUT masks is non-inferior to that obtained with two of the three released detectors evaluated. A variant built on an openly licensed foundation model is publicly released as an installable Python package with trained weights. These results support risk-guided foundation-model inference as an effective approach to tissue detection across heterogeneous histopathology data.

0.28

FedHisto-PAST: Parameter-Efficient Stain-Aware Federated Learning for Cross-Site Lung Histopathology Classification

cs.CV cs.AI ·2026-09-25 ·Muhammad Muhtasim Shahriar, M. M. Golam Hafiz, Saad Aloteibi, Mohammad Ali Moni
similarity 0.63
Abstract · Submitted to Engineering Applications of Artificial Intelligence (Elsevier)

Cross-site lung histopathology classification must account for stain variation, non-IID client data, missing classes, and the cost of adapting large pathology encoders. This study evaluates FedHisto-PAST v2 for three-way classification of adenocarcinoma (ACA), Normal, and squamous cell carcinoma (SCC). FedHisto-PAST v2 combines a frozen HIBOU-B foundation model with parameter-efficient adaptation, stain-conditioned paired-view prediction and feature consistency, reliability-aware prototype learning, and adaptive federated aggregation. Experiments used a five-client, non-IID, raw-data-local simulation with fixed internal evaluation, client-level analysis, component ablations, communication accounting, and a development-influenced exploratory LungHist700 cohort. All principal methods achieved near- ceiling internal performance, which limited discrimination on the fixed split. On LungHist700, FedHisto- PAST v2 achieved a Macro-F1 of 0.728560 and a balanced accuracy of 0.730454. Higher recognition of Normal and SCC was accompanied by lower ACA recall, and calibration remained imperfect. Prediction-level consistency was the only component with a clearly supported independent contribution in the external ablation analysis. Feature consistency and prototype regularization showed no conclusive independent overall gains in Macro-F1. The framework updated 1.253841% of the model parameters. The results provide exploratory cross-dataset evidence for stain-aware, parameter-efficient federation; they do not establish formal privacy, patient-level independence, prospective deployment, or clinical validation.

0.26

From Slices to Volumes: Comparing 2D, 2.5D, and 3D Residual Networks for Pulmonary Nodule Malignancy-Risk Classification

cs.LG cs.CV ·2026-10-25 ·Bahodir Nazarov, Zineb Gharib, Fatima Zazoul
code/data similarity 0.63
Abstract

Purpose: To compare 2D, 2.5D, and 3D residual networks for pulmonary nodule malignancy-risk classification and evaluate momentum-contrast pretraining, mild augmentation, and exclusion of indeterminate ratings. Methods: A retrospectively prepared LIDC-IDRI cohort contained 2,654 nodules labeled benign, indeterminate, or malignant using median radiologist ratings. Patient-disjoint splits comprised 1,876 training, 382 validation, and 396 test nodules. Representations included one axial slice, five neighboring slices, and a local CT volume. Each track evaluated a randomly initialized baseline, momentum-contrast pretraining followed by fine-tuning, and supervised training with mild augmentation. Checkpoints were selected by validation Macro-F1. The 2D experiments used three seeds; 2.5D and 3D results were single-run estimates. A separate binary experiment excluded indeterminate nodules. Results: Augmented models achieved test Macro-F1 values of $0.6134\pm0.0075$ for 2D, $0.6537$ for 2.5D, and $0.5403$ for 3D; the 2D uncertainty denotes population standard deviation across seeds. Corresponding accuracies were $0.6128$, $0.6869$, and $0.5455$. Augmentation improved Macro-F1 within every track, whereas the tested pretraining recipes reduced it. Binary Macro-F1 values were $0.8227$, $0.8664$, and $0.7554$, respectively. Conclusion: Augmented 2.5D achieved the highest observed performance. Differences in preprocessing, optimization, capacity, and replication limit attribution to dimensionality. Labels reflect radiologist-assessed malignancy risk rather than pathology-confirmed cancer. Code and experimental results are available at https://github.com/CT-DeepLearning-Team/CT-2D-2.5D-3D-DeepLearning.

0.18

AI-based characterization of lymphoid structures and the tumor microenvironment reveals lower mature tertiary lymphoid structures, lymph-node follicles, and plasma cells after neoadjuvant therapy in lung squamous cell carcinoma

cs.CV q-bio.QM ·2026-11-09 ·Arne Schmidt, Justin Nieder, Cornelius Boehm, Julika Ribbat-Idel, Marius Teodorescu +22 more
similarity 0.63
Abstract

Mature, germinal centre-bearing tertiary lymphoid structures (TLS) and mature lymph node follicles (secondary lymphoid structures, SLS) sustain the plasma cell response that shapes outcome and immunotherapy benefit in lung cancer. How this loco-regional axis differs between neoadjuvant-treated and therapy-naive tumors is poorly defined. We analyzed H&E whole-slide images of resected tumors and paired proximal and distal lymph nodes from matched neoadjuvant-treated (neoLUSC, n=20) and therapy-naive (naivLUSC, n=20) lung squamous cell carcinoma (LUSC) patients. Aignostics Atlas H&E Tissue Analysis (HETA) models quantified cell densities per tissue compartment and cell-cell co-localization; a dedicated deep-learning model validated against pathologist annotations detected TLS and SLS and graded their maturity. Prognostic value was tested in an independent cohort (n=458; 46 treated). In neoLUSC tumors, stromal plasma cell density was 72% (p=0.004) and stromal lymphocyte density 48% (p=0.015) lower than in naivLUSC; macrophages and granulocytes did not differ significantly. Total and immature TLS did not differ, whereas mature TLS in the tumor (p=0.034) and mature SLS in the tumor-distal lymph node (p=0.003) were lower in neoLUSC patients. Peri-TLS plasma cell density correlated with tumor lymphocyte density in naivLUSC (rho=0.54, p=0.017) but not in neoLUSC tumors (rho=0.07). In the validation cohort, stromal plasma cell density (HR 0.69, p=0.011) and lymphocyte-plasma cell co-localization (HR 0.66, p=0.004) were associated with longer survival, and neoadjuvant status with shorter survival (HR 1.50, p=0.026). Neoadjuvant therapy is thus associated with fewer mature lymphoid structures and weaker coupling of the humoral compartment to the tumor rather than uniformly lower immune readouts. The stromal plasma cell/co-localization axis is a candidate prognostic biomarker.

0.31

LUCAID: Agentic Multimodal AI for Lung Cancer Precision Pathology

cs.CV cs.AIcs.LG ·2026-08-24 ·Marie-Lisa Eich, Kai Standvoss, Timo Milbich, Alexander Möllers, Miriam Hägele +28 more
similarity 0.63
Abstract

Lung cancer tissue diagnostics is complex, as therapy decisions in precision oncology rely on the integration of histomorphological, immunohistochemical, and molecular features. Yet pathological assessment remains largely visual and semi-quantitative and shows interobserver variability, while existing artificial intelligence (AI) tools cover only selected tasks, rarely reach generalizable expert-level performance, and lack prospective clinical validation. To address these challenges, we developed and clinically validated LUCAID, an agentic AI system for precision lung cancer pathology. An integrative agent couples diagnostic reasoning with nine modules that cover the full routine workflow, from quality control, tumor detection and segmentation, histological subtyping, tumor microenvironment profiling, tumor cellularity quantification, and predictive biomarker scoring (PD-L1, MET, TROP-2) to automated structured report generation. LUCAID enables users to interactively query the module outputs and generate reports that contextualize the results. Against large-scale expert ground-truth annotations, the analysis modules achieved F1 scores of 0.82-0.95. In prospective clinical validation, LUCAID reached 93.0% concordance with an expert-panel adjudicated reference standard across clinically actionable decisions, compared with 68.3-81.1% for five experienced thoracic pathologists.

0.26

Beyond Discrimination: Evaluating Probability Calibration in Radiomics-Image Fusion for Renal Cell Carcinoma Classification

eess.IV cs.AIcs.CVq-bio.QM ·2026-10-09 ·Yuan Liang, Morgan May, Abraham Campbell, Sourav Bhattacharjee, Simon Caton +1 more
top venue similarity 0.62
Abstract · 12 pages. 1 figure. Accepted at the 2026 Irish Conference on Artificial Intelligence and Cognitive Science (AICS 2026). Proceedings forthcom…

Reliable probability estimates are important for the clinical interpretation of machine-learning classifiers, yet radiomics--image fusion models for renal cell carcinoma (RCC) are commonly evaluated primarily by discrimination. Using 396 patients from the KiTS23 dataset, we evaluated whether adding radiomics to four image-model families improved probabilistic performance in addition to discrimination. Seventeen individual models and four probability-average ensembles were assessed using discrimination, probability calibration, and proper scoring measures. Across 12 matched image-only versus fusion comparisons, AUC and AP improved in all 12, while Brier score and negative log likelihood (NLL) improved in 11 of 12 and expected calibration error (ECE) in eight of 12. The 3D MedVAE gated-fusion model achieved the strongest overall individual-model profile. Probability averaging across concatenation, cross-attention, and gated fusion produced favourable point estimates across all five primary metrics relative to image-only models in all four families, although paired-bootstrap support was stronger for Brier score and NLL than for ECE. These findings show that radiomics--image fusion can improve probabilistic prediction quality beyond discrimination, while calibration behaviour varies across image architectures and fusion strategies. We show that our proposed probability-average ensemble models improve discrimination and calibration simultaneously across all architectures in the study.

0.38

Morphology signal in whole slide image foundation models can automatically triage slides

cs.CV cs.LG ·2026-09-02 ·Ayushi Sinha, Shashank Yadav, Benjamin Holmes, Pravat Das, Aaron W. Bogan +7 more
benchmark similarity 0.62
Abstract · 12 pages, 3 figures, 4 tables

Patient exams in the cancer diagnosis and staging process typically generate several whole slide images (WSIs). One of the initial steps in training models on WSI data is identifying one or a few slides containing tumor or other diagnostic biomarkers necessary for downstream prediction tasks such as estimating recurrence risk or progression-free survival. This step requires tedious manual curation by experienced pathologists. Many published datasets make the artificial assumption of 1 slide per patient. Alternatively, all slides per patient may be used for model training, which may dilute the signal from the few slides containing tumor or other relevant information. In this paper, we present a pipeline to overcome these challenges using publicly available WSI foundation models (FMs). Our evaluations show that ranking WSIs based on predictions from zero-shot classification using WSI FMs accurately identifies slides with the most tumor, indicating that WSI FMs contain sufficient morphology signal to automatically triage slides. We also present a formulation for ranked evaluation to benchmark FM performance in slide triage. We show, on multiple datasets, that tumor slides are identified in the top-2 ranked slides for patients with up to 43 slides.

0.14